Catalog No.
Product Name
Application
Product Information
Citations
-
17β-HSD2 Inhibitor
11β-HSD2-IN-2 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 2 (17β-HSD2), demonstrating an IC50 of 300 nM. This compound plays a crucial role in modulating steroid metabolism and is valuable for research applications investigating hormonal regulation and related disorders. Its specificity makes it a useful tool for exploring the biological effects of 17β-HSD2 inhibition in various physiological contexts. -
HSD17B13 Inhibitor
BI-3231 is a potent and selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating IC50 values of 1 nM and 13 nM for human and mouse HSD17B13, respectively. This compound is valuable for research into nonalcoholic steatohepatitis (NASH) and various liver disorders, facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers a promising avenue for understanding and potentially treating these conditions. -
AKR1C3 Inhibitor
AKR1C3-IN-4 is a potent and selective inhibitor of aldo-keto reductase 1C3 (AKR1C3), exhibiting an IC50 value of 0.56 μM. This compound is particularly relevant for investigations into castrate-resistant prostate cancer (CRPC), where AKR1C3 plays a crucial role in tumor progression and hormone regulation. Its mechanism facilitates the exploration of therapeutic strategies targeting metabolic pathways in cancer research. -
17β-HSD1 Inhibitor
17β-HSD1-IN-1 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1), exhibiting IC50 values of 5.6 nM for 17β-HSD1 and 3155 nM for 17β-HSD2. This compound plays a crucial role in modulating estrogen levels and is pertinent for research focused on non-small cell lung cancer (NSCLC). Its specificity enables targeted studies into the enzymatic pathways associated with hormone-driven tumorigenesis. -
Non-alcoholic steatohepatitis
Rapirosiran sodium is an N-acetylgalactosamine-conjugated small-interfering RNA that specifically targets hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) mRNA in the liver. It is associated with a reduction in the risk of chronic liver diseases due to loss-of-function variants in the HSD17B13 gene. This reagent is particularly valuable for research focused on non-alcoholic steatohepatitis, facilitating the exploration of therapeutic strategies targeting liver metabolism and inflammation. -
Non-alcoholic steatohepatitis
Rapirosiran is an N-acetylgalactosamine-conjugated small interfering RNA that specifically targets mRNA of hydroxysteroid 17-beta dehydrogenase 13 (HSD17B13) in the liver. Inhibition of HSD17B13 via Rapirosiran is associated with a reduced risk of chronic liver disease. This reagent is valuable for investigating the mechanisms of non-alcoholic steatohepatitis and exploring potential therapeutic approaches. -
AKR1C3 Inhibitor
S07-1066 is a selective inhibitor of aldo-keto reductase 1C3 (AKR1C3) that enhances the cytotoxic effects of doxorubicin (DOX). By inhibiting the AKR1C3-mediated reduction of DOX, S07-1066 effectively reverses drug resistance in cells that overexpress this enzyme. This compound is valuable for research applications investigating chemotherapy resistance and potential adjuvant therapies in cancer treatment. -
17β-HSD10 Inhibitor
17β-HSD10-IN-1 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), exhibiting oral bioavailability and effective blood-brain barrier penetration. This compound is characterized by a selective mechanism of action that minimizes off-target effects on mitochondria, along with a favorable safety profile devoid of cytotoxic or neurotoxic effects. It is suitable for research applications focused on disorders related to steroid metabolism and neurodegenerative diseases. -
HSD17B1 Inhibitor
Linustedastatum is an orally active inhibitor of hydroxysteroid 17-beta dehydrogenase 1 (HSD17B1). This compound exhibits significant biological activity by modulating the biosynthesis of estrogens, making it a valuable tool for research applications related to endometriosis. Its mechanism of action provides insights into hormonal pathways and potential therapeutic targets in gynecological disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-2 is a selective inhibitor of HSD17B13, demonstrating human IC50 values of 0.18 μM with β-estradiol and 0.25 μM with Leukotriene B4. This compound binds to the active site of HSD17B13 in an NAD+-dependent manner, interacting with the bound NAD+ cofactor to stabilize the HSD17B13 protein and prevent its aggregation. HSD17B13-IN-2 effectively reduces the conversion of β-estradiol to estrone in cellular assays, making it a valuable tool for investigating nonalcoholic fatty liver disease and related metabolic disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-3 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of 0.38 μM and 0.45 μM in biochemical assays using β-estradiol and Leukotriene B4 (LTB4) as substrates, respectively, in the presence of NAD+ as a cofactor. This compound is useful for studying the role of HSD17B13 in steroid metabolism and has potential applications in research related to metabolic disorders and inflammatory conditions. However, it exhibits low cell penetration, which may limit its use in certain cellular assays. -
HSD17B13 Inhbitor
HSD17B13-IN-9 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases 13 (HSD17B13), exhibiting an IC50 of 0.01 μM against 50 nM HSD17B13. This compound plays a significant role in the investigation of nonalcoholic fatty liver diseases (NAFLD) by modulating steroid metabolism and related pathways. Its potent inhibitory effects make it a valuable tool for research into hepatic lipid metabolism and associated disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-8 is an inhibitor of 17β-hydroxysteroid dehydrogenases (HSD17B13), demonstrating potent inhibitory activity with IC50 values of less than 0.1 μM for estradiol and less than 1 μM for LTB3. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), allowing for deeper investigation into the metabolic pathways involved in liver disorders. -
Anticancer Agent
Odafosfamide is a selective prodrug bis-alkylating agent that is activated by aldehyde-keto reductase 1C3 (AKR1C3). It exhibits potent cytotoxicity in cell lines that express high levels of AKR1C3, demonstrating significant antitumor activity in various cancers, including liver cancer, non-small cell lung cancer, and leukemia. This compound is suitable for use in cancer research to investigate mechanisms of action and therapeutic potential in malignancies characterized by elevated AKR1C3 expression. -
HSD17B13 Inhibitor
HSD17B13-IN-10 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of 0.01 μM. This compound is valuable in researching liver diseases by modulating steroid metabolism and influencing lipid and glucose homeostasis. Its selective inhibition makes it a critical tool for studying the pathogenic mechanisms underlying hepatic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-43 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its ability to modulate steroid metabolism makes it a significant tool for research into liver function and disease mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-41 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13). This compound demonstrates potential in modulating pathways associated with liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its application in research can aid in understanding the underlying mechanisms of these diseases and support the development of novel therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-29 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is a valuable tool for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as metabolic and cardiovascular disorders. Its selectivity for HSD17B13 positions it as a significant reagent for investigating therapeutic strategies targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-49 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into various liver-related conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies on drug-induced liver injury (DILI). Its inhibition of HSD17B13 may provide insights into potential therapeutic strategies for metabolic and cardiovascular disorders linked to liver dysfunction. -
HSD17B13 Inhibitor
HSD17B13-IN-69 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an impressive IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition profile makes HSD17B13-IN-69 a crucial tool for exploring therapeutic strategies and understanding disease mechanisms. -
HSD17B13 Inhibitor
HSD17B13-IN-67 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is instrumental in studying liver diseases and metabolic disorders, providing valuable insights into the role of HSD17B13 in these conditions. Its high specificity and efficiency make it a useful tool for researchers investigating the therapeutic potential of targeting HSD17B13. -
17β-HSD10 Inhibitor
17β-HSD10-IN-2 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10), a multifunctional enzyme located in the mitochondria. This compound demonstrates significant inhibition of 17β-HSD10 without causing off-target effects on mitochondrial function or exhibiting cytotoxic and neurotoxic properties. 17β-HSD10-IN-2 is valuable for research applications focused on Alzheimer's disease and hormone-dependent cancers, facilitating the exploration of therapeutic strategies targeting this enzyme. -
HSD17B13 Inhibitor
HSD17B13-IN-73 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool for investigating the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic strategies targeting these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-70 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to liver diseases and metabolic disorders, providing critical insights into the enzymatic regulation of steroid metabolism. HSD17B13-IN-70 serves as a valuable tool for investigators studying the role of HSD17B13 in various biological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-97 is a highly potent inhibitor of hydroxysteroid 17ß-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤0.1 µM. This compound holds promise for investigating therapeutic strategies for nonalcoholic fatty liver diseases (NAFLDs), nonalcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition of HSD17B13 makes it a valuable tool for exploring lipid metabolism and liver pathology in preclinical research. -
17β-HSD5 Inhibitor
17β-HSD5 Inhibitor 3 is a selective inhibitor of the enzyme 17β-HSD5, exhibiting an IC50 value of 69 nM. This compound plays a crucial role in modulating steroid metabolism and can be utilized in research related to steroid-related disorders and hormonal regulation. Its oral bioactivity makes it a valuable tool for exploring therapeutic approaches in conditions influenced by 17β-HSD5 activity. -
HSD17B13 Inhibitor
HSD17B13-IN-15 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 1 μM for leukotriene B3 and ≤ 0.1 μM for estradiol. This compound is of significant interest in the study of various liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. HSD17B13-IN-15 provides valuable insights for research related to drug-induced liver injury (DILI) and potential therapeutic interventions. -
HSD17B13 Inhibitor
HSD17B13-IN-93 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 for estradiol within the range of 0.1 to 0.5 μM. This compound is valuable for investigating the role of HSD17B13 in liver pathologies, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-93 serves as a critical tool for advancing research in these areas. -
HSD17B13 Inhibitor
HSD17B13-IN-6 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of 0.01 μM. This compound is valuable for investigating the role of HSD17B13 in liver diseases, providing insights that may contribute to the understanding of metabolic disorders and potential therapeutic targets. Researchers can utilize HSD17B13-IN-6 to explore biochemical pathways associated with liver function and disease processes. -
HSD17B13 Inhibitor
HSD17B13-IN-80-d2 is a deuterium-labeled inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is essential for investigating the role of HSD17B13 in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its unique labeling enhances tracking and analysis in metabolic research applications. -
17β-HSD10 Inhibitor
17β-HSD10-IN-3 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10) with an IC50 value of 5.59 μM. This compound demonstrates a lack of cytotoxicity in the HEK-293 cell line at concentrations up to 20 μM. It is suited for research applications investigating the role of 17β-HSD10 in steroid metabolism and neurodegenerative diseases. -
HSD17B13 Inhibitor
HSD17B13-IN-76 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for research into liver diseases and metabolic disorders, facilitating studies on the biochemical pathways regulated by HSD17B13 and its role in steroid metabolism. -
17β-HSD3 Inhibitor
BMS-856 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3). It demonstrates potent inhibitory activity with IC50 values of 60 nM in enzyme assays and 300 nM in whole cell assays, effectively disrupting the enzyme's activity. BMS-856 is valuable for research focused on steroidogenesis and potential therapeutic applications in hormonal disorders, particularly those related to testosterone metabolism. -
HSD17B13 Inhibitor
HSD17B13-IN-74 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of less than 0.1 μM for estradiol. This compound serves as a valuable tool in the study of liver diseases and metabolic disorders, enabling the exploration of HSD17B13's role in steroid metabolism. Its potent inhibition can facilitate research into therapeutic strategies targeting related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-86 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its ability to modulate HSD17B13 activity makes it a useful tool in the exploration of therapeutic strategies for these conditions. -
HSD17B13 Inhibitor
HSD17B13-IN-52 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research focused on liver conditions, metabolic disorders, and cardiovascular diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as studies related to drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-103 is a selective inhibitor of the enzyme HSD17B13. This compound demonstrates potential in research focused on non-alcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). Its inhibition of HSD17B13 may provide insights into therapeutic strategies for metabolic liver diseases. -
17β-HSD3 Inhibitor
SCH-451659 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase type 3 (17β-HSD3) with an IC50 of 2.4 nM. By blocking the conversion of androstenedione to testosterone, SCH-451659 effectively lowers testosterone levels in vivo. This compound exhibits potential anticancer activity, particularly against prostate tumors that depend on androstenedione. Its specific targeting mechanism makes SCH-451659 a valuable reagent for research in hormone-related cancer therapies. -
HSD17B13 Inhbitor
HSD17B13-IN-62 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver diseases (NAFLD), providing valuable insights into the mechanisms of lipid metabolism and hormone regulation. Its application may aid in the development of therapeutic strategies targeting liver dysfunction and associated metabolic disorders. -
17β-HSD Inhibitor
HSD17B13-IN-17 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting IC50 values of less than 0.1 μM for estradiol and under 1 μM for Leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). HSD17B13-IN-17 is essential for research focused on the modulation of lipid metabolism and the therapeutic potential of HSD17B13 inhibitors in liver-related disorders. -
HSD17B13 Inhibitor
HSD17B13-IN-66 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for researching liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its specificity and efficacy make it a promising tool for elucidating the role of HSD17B13 in various pathophysiological processes. -
HSD17B13 Inhibitor
HSD17B13-IN-65 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is instrumental in research focused on liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted action on HSD17B13 allows for the exploration of therapeutic strategies in these areas. -
17β-HSD Inhibitor
HSD17B13-IN-27 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is instrumental in research involving nonalcoholic fatty liver diseases (NAFLD), including nonalcoholic steatohepatitis (NASH). Its ability to modulate steroid hormone metabolism positions it as a valuable tool for studying metabolic disorders and developing therapeutic strategies. -
HSD17B13 Inhibitor
HSD17B13-IN-13 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver pathologies, including non-alcoholic fatty liver disease (NAFLD). Its potent inhibitory activity makes it a useful tool for elucidating the biochemical mechanisms underlying liver disorders and developing therapeutic strategies. -
17β-HSD Inhibitor
HSD17B13-IN-19 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol and below 1 μM for leukotriene B3. This compound is significant in the context of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its inhibition of HSD17B13 may provide insights into therapeutic strategies for managing liver-related metabolic disorders. -
HSD17B13 Inhbitor
HSD17B13-IN-80-d3 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and may serve as a valuable tool for studying metabolic regulation and liver-related pathologies. -
HSD17B13 Inhibitor
HSD17B13-IN-75 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-75 can be utilized in studies focused on drug-induced liver injury (DILI). -
HSD17B13 Inhibitor
HSD17B13-IN-46 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is utilized in research focused on liver diseases and metabolic disorders, providing valuable insights into the modulation of steroid hormone regulation and related pathophysiologies. Its high specificity and efficacy make it a significant tool for further investigations in these areas. -
HSD17B13 Inhibitor
HSD17B13-IN-32 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound demonstrates significant potential for research applications in liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its selective inhibition may facilitate the investigation of HSD17B13's role in these pathologies. -
17β-HSD5 Inhibitor
EM 1404 is a potent inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17β-HSD5) with an IC50 of 3.2 nM. This compound plays a crucial role in modulating androgen metabolism and has significant implications in the study of hormone-related disorders. EM 1404 is valuable for research focused on exploring therapeutic strategies for conditions associated with altered steroid hormone levels.
